PRINT-CHEMO · To develop 3D bioPRINTed osteoinductive constructs that deliver CHEMOtherapeutics within large bone defects that are surgically created when removing bone tumours.
„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“
- Период
- 2019-07-01 → 2022-06-30
- Финансиране от ЕС
- 257 561 €
- Участници
- 2
- Схема
- MSCA-IF
Линиите свързват координатора с партньорите.
Накратко на български
Локалното доставяне на miR-29b чрез наночастици при пациенти с остеосаркома помага за потискане на туморите и възстановяване на костта. Това е важно, защото стандартната химиотерапия често пречи на регенерацията на костните тъкани след хирургичното отстраняване на тумора.
Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.
Резултати накратко
To develop 3D bioPRINTed osteoinductive constructs that deliver CHEMOtherapeutics within large bone defects that are surgically created when removing bone tumours.
Patients who are diagnosed with osteosarcoma today, will receive the same standard-of-care regimen, that was first introduced in the late 1970s — tumour resection and chemotherapy — resulting in dismal prognosis. The use of tissue engineering strategies after malignant tumour resection remains a subject of scientific controversy. As a result, there is limited research that focuses on bone regeneration postresection. Furthermore, although chemotherapy is effective in controlling cancer cell growth, it also significantly hinders the bone’s ability to regenerate. Therefore, any bone regeneration strategy that would enhance bone regeneration, would be of great interest to these young patients. Motivated by this, this MSCA fellowship investigated if localised delivery of miR-29b—which has been shown to promote bone formation by inducing osteoblast differentiation and also to suppress prostate and glioblastoma tumour growth—would suppress osteosarcoma tumour growth and enhance the therapeutic potential of chemotherapy whilst simultaneously providing the surrounding damaged bone the necessary cues for repair. The scientific team developed a formulation of miR-29b:nanoparticles that were delivered via an injectable system which crosslinked in situ to enable local and sustained release of the therapy. The study’s main findings showed that when miR-29b was delivered along with systemic chemotherapy, compared to chemotherapy alone, the therapy provided a 45% decrease in tumour burden, a significant increase survival, and a 75% reduction in bone osteolysis caused by the tumour and/or chemotherapy. This anti-cancer and pro-osteogenic effect of miR-29b delivery may extend to other types of cancer. As bone is one of the most common locations of cancer cell metastasis, any therapeutic that inhibits bone tumour growth whilst simultaneously aiding in bone regeneration while the patient is undergoing chemotherapy would significantly benefit not only osteosarcoma patients but any cancer patient with bone metastases.
Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз
Цел на проекта
Osteosarcoma is the most commonly diagnosed bone tumour with most of these cases being in children and adolescents. Each year over 4,000 new cases of osteosarcoma are diagnosed in the United States. Osteosarcoma predominantly initiates in the metaphysis of long bones, such as the distal femur, proximal tibia and proximal humerus. Over 50% of these tumours are relatively resistant to radiation therapy, due to the molecular aberration of the tumour. The current gold standard for treatment is tumour resection and adjuvant chemotherapy, with a 5-year survival rate of 61.6% in patients aged 0-24 years old. Approximately one-third of patients diagnosed with osteosarcoma are expected to have a relapse, with only 15% of these patients surviving the disease a second time. Therefore, due to the young age of initial diagnosis, the management of this disease is a challenging and costly exercise, which has a significant socioeconomic cost, estimated to be €14.7 billion in Europe and $45 billion in the USA in the last 18 years. While significant progress has been made in trying to understand the intra-tumour heterogeneity and the evolutionary pattern of a subset of clones within the tumour, thus far, no major changes in treatment and outcome have been achieved. The hypothesis of PRINT-CHEMO is that localised delivery of self-assembled dendritic nanoparticles used as a first wave of treatment to deliver miR-194, a tumour suppressive gene, to the cells along with the delivery of nanoparticles loaded with chemotherapeutics would lead to higher survival rates and less side effects than systemic delivery of a higher dose of drug. Furthermore, PRINT-CHEMO not only aims to treat the diseased tissue but using 3D printing provide the necessary cues to allow for the body to regenerate the damaged bone caused due to tumour resection.
Оригинален текст от CORDIS (на английски).
Участници
- THE PROVOST, FELLOWS, FOUNDATION SCHOLARS & THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY & UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN · DublinКоординаторИрландия
- BRIGHAM INC · BostonСъединени щати
Връзки
Данни: CORDIS, © Европейски съюз